Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

3 1 1

What is this study about?

This clinical trial is focused on studying the effects of a medication called ustekinumab in children with a condition known as ulcerative colitis. Ulcerative colitis is a disease that causes inflammation and sores in the lining of the large intestine, which can lead to symptoms like abdominal pain and diarrhea. The study aims to understand how well ustekinumab works in helping children achieve remission, which means reducing or eliminating the symptoms of the disease.

Participants in the study will receive ustekinumab in two different forms. Initially, it will be given as an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. This is followed by regular doses given as a subcutaneous injection, which is an injection under the skin. The study will also include a comparison with a placebo, which is a substance with no active medication, to help understand the true effects of ustekinumab.

The study will take place over a period of time, during which participants will receive the medication and be monitored for any changes in their condition. The goal is to evaluate the safety and effectiveness of ustekinumab in managing ulcerative colitis in children, as well as to study how the body processes the medication. This research is important for developing better treatments for children with this challenging condition.

1 initial treatment

Upon joining the study, the first step involves receiving an initial treatment with the medication ustekinumab. This is administered through an intravenous infusion, which means the medication is given directly into a vein. The specific product used is STELARA 130 mg concentrate for solution for infusion.

2 maintenance treatment

Following the initial treatment, the next phase is the maintenance treatment. This involves receiving ustekinumab through a subcutaneous injection, which means the medication is injected under the skin. The products used are either STELARA 90 mg solution for injection in pre-filled syringe or STELARA 45 mg solution for injection.

The frequency and dosage of these injections will be determined by the study protocol and communicated by the healthcare team.

3 monitoring and assessments

Throughout the study, regular monitoring and assessments will be conducted to evaluate the effectiveness and safety of the treatment. This includes physical examinations, medical history reviews, and vital sign checks.

Participants will also undergo endoscopic evaluations to assess the condition of the colon, ensuring the treatment is working as intended.

4 completion of study

The study is expected to continue until June 2025. Upon completion, participants will undergo final assessments to determine the overall impact of the treatment on their condition.

The primary goal is to achieve clinical remission by Week 8, which means the symptoms of ulcerative colitis are significantly reduced or absent.

Who Can Join the Study?

The patient must be medically stable based on a physical exam, medical history, and vital signs. Any unusual findings should be related to the condition being studied and noted by the doctor.
The patient must have been diagnosed with Ulcerative Colitis (UC) before the screening.
The patient must have moderately to severely active UC, which means having a specific score (Mayo score) between 6 and 12, and a certain result from an endoscopy test.
If the patient has had extensive colitis for 8 years or more, or disease limited to the left side of the colon for 10 years or more, they must have had a full colonoscopy within the last year to check for abnormal cell growth (dysplasia) or have one during the screening period. The results must show no dysplasia before starting the study treatment.
Females who can have children must have a negative pregnancy test at the screening and before starting the study treatment.

Who Cannot Join the Study?

Patients with any other significant health condition that could interfere with the study.
Patients who have had a recent infection that required treatment with antibiotics or other medications.
Patients who have received any other investigational drug within a certain period before the study.
Patients who have a history of allergic reactions to the study medication or similar medications.
Patients who are pregnant or breastfeeding.
Patients who have a history of certain types of cancer.
Patients who have a history of certain blood disorders.
Patients who have a history of certain liver or kidney diseases.
Patients who have a history of drug or alcohol abuse.
Patients who are unable to comply with the study procedures or follow-up visits.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Katholieke Universiteit te Leuven	Leuven	Belgium

Other Sites

Site Name	City	Country
Instytut Pomnik Centrum Zdrowia Dziecka	Warsaw	Poland
Semmelweis University	Budapest	Hungary
Borsod-Abauj-Zemplen Varmegyei Koezponti Korhaz Es Egyetemi Oktatokorhaz	Miskolc	Hungary
Gastromed Sp. z o.o.	Torun	Poland
Copernicus Podmiot Leczniczy Sp. z o.o.	Gdansk	Poland
University Of Debrecen	Debrecen	Hungary
Universitaetsklinikum Erlangen AöR	Erlangen	Germany
Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz	Nyiregyhaza	Hungary
Barmherzige Brueder gemeinnuetzige Krankenhaus GmbH	Regensburg	Germany
Universitair Ziekenhuis Gent	Gent	Belgium
Universitaetsklinikum Aachen AöR	Aachen	Germany
Deutsches Herzzentrum Berlin	Berlin	Germany
Vrije Universiteit Brussel	Jette	Belgium
University Childrens Hospital Queen Fabiola	Brussels	Belgium
Uniwersytecki Szpital Dzieciecy W Krakowie	Cracow	Poland
University Of Szeged	Szeged	Hungary
MD Korczowski Bartosz Gabinet Lekarski	Rzeszow	Poland
Lhctvl Mqiusbxory Udqrnmzdja Ox Mshhqi	Munich	Germany
Cowyeaesb Usbbhcjwsnlzff Sbrxeuhui	Woluwe-Saint-Lambert	Belgium
Upydpzunzi Hxhrejob Cbmyult	Cologne	Germany
Uyqltidcyrmfuvxybgenz Enfbm Ans	Essen	Germany
Wcl Wzkyyf Iiy Pnsda Pdlbpive Kqwupdz	Warsaw	Poland

Trial status

Country	Status	Recruitment Start
Belgium	Not recruiting	15.01.2021
Germany	Not recruiting	15.01.2021
Hungary	Not recruiting	15.01.2021
Poland	Not recruiting	15.01.2021

Trial locations

Investigated drugs:

Ustekinumab

Ustekinumab is a medication used in this clinical trial to help treat children with a condition called ulcerative colitis, which causes inflammation and sores in the large intestine. This medication works by targeting specific proteins in the body that are involved in the inflammation process. By doing so, it helps reduce the symptoms of ulcerative colitis, such as abdominal pain and diarrhea, and aims to bring the disease into remission, meaning the symptoms are reduced or disappear. In this study, the medication is first given through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein, and then it is given as an injection under the skin to maintain its effects over time. The trial is designed to assess how well this medication works, how safe it is for children, and how the body processes it.

Ulcerative Colitis – Ulcerative colitis is a chronic inflammatory condition affecting the colon and rectum. It is characterized by continuous inflammation of the innermost lining of the large intestine, leading to the formation of ulcers. The disease typically begins in the rectum and may extend to involve the entire colon. Symptoms often include abdominal pain, diarrhea, and rectal bleeding. The inflammation can cause frequent and urgent bowel movements. Over time, the disease can lead to complications such as severe bleeding or perforation of the colon.

Trial ID:

2023-504977-19-00

Protocol code:

CNTO1275PUC3001

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?